AMA and EMA Issue Joint Guidance on Bundibugyo Ebola Vaccine Clinical Trial Requirements

Platform manufacturers developing mRNA and viral-vector vaccines for Ebola disease caused by Bundibugyo virus (BDBV) now have a defined regulatory pathway, following a joint position paper published by EMA's Emergency Task Force (ETF) and the African Medicines Agency (AMA). The document sets minimum requirements for clinical trial initiation and carries direct implications for toxicology study design, trial geography, and engagement timelines with African national regulatory authorities (NRAs).

The paper was developed after a scientific consultation convened by AMA, EMA, and WHO on 24 August 2026, against the backdrop of an ongoing public health emergency in the Democratic Republic of the Congo, with cases also confirmed in Uganda, Kenya, and Nigeria. The urgency of that epidemiological context is embedded in the guidance's core logic: accelerate development without compromising participant safeguards, including for vulnerable groups such as children and pregnant women.

For QA and regulatory leads, the most operationally significant provision concerns animal toxicity studies. The position paper permits postponement or waiver of certain non-clinical studies where a vaccine platform carries well-characterised safety data and where different antigens have not materially altered the overall safety profile. This applies specifically to mRNA and select viral-vector platforms with existing cross-antigen safety records, a framing that aligns with precedents established during COVID-19 vaccine development but now formalised for BDBV candidates.

Trial design requirements are equally specific. Non-human primate challenge studies must be completed before progression to Phase II/III, providing proof of biological activity prior to efficacy evaluation in human populations. The guidance favours a single-dose regimen to support rapid outbreak deployment logistics. For pivotal Phase III assessment, a ring trial design, enrolling individuals with confirmed close contact with a BDBV case, is proposed as the primary efficacy framework, with provision for evaluating multiple candidates within a single platform trial.

Early-phase trials are expected to be conducted within the African region to streamline the transition to larger efficacy studies in affected populations. Developers are explicitly directed to initiate regulatory dialogue with AMA and relevant African NRAs at the earliest stage, covering scientific advice, clinical trial assessment, and authorisation requirements. The guidance also calls on NRAs to expedite trial approvals in recognition of the active outbreak context.

Studies in paediatric and pregnant populations are required once adult safety data reaches a sufficient threshold, a sequencing requirement that will shape clinical development plans and informed consent frameworks for sponsors already in early-stage work.

The measurable checkpoint ahead is NRA approval timelines for BDBV trial applications submitted under the new framework, which will indicate how effectively the joint guidance translates into accelerated regulatory action across African jurisdictions.

Source: European Medicines Agency (EMA) via ema.europa.eu, 23 October 2026.